Cardiff Oncology Earnings Call Transcripts
Fiscal Year 2026
-
KOLs reviewed promising phase II data for onvansertib plus FOLFIRI+BEV in first-line RAS mutated metastatic CRC, highlighting a 72% response rate, strong PFS trends, and favorable tolerability. The 30 mg dose will advance to phase III, addressing a major unmet need for this patient group.
-
Onvansertib, a selective PLK1 inhibitor, demonstrated a 72% ORR and promising PFS in first-line RAS-mutated mCRC, with no significant added toxicity. Plans are underway for a global phase III trial, with regulatory discussions and more data expected in the first half of the year.
-
Promising phase II data show that onvansertib plus FOLFIRI-Bev achieved a 72.2% response rate and extended PFS in first-line RAS-mutated mCRC, with favorable safety. The 30 mg dose will advance to a registrational trial, with further data and regulatory updates expected in 2026.
Fiscal Year 2025
-
Onvansertib demonstrates robust efficacy and safety in RAS-mutated metastatic colorectal cancer, with strong early clinical results and FDA-aligned plans for a registrational trial. Strategic partnerships and a solid cash position support continued progress and market potential.
-
Onvansertib, a selective oral PLK1 inhibitor, showed promising efficacy and safety in phase II for RAS-mutated metastatic colorectal cancer, with a 19% higher response rate at the optimal dose and no significant added toxicity. Plans include a phase III trial and data update in Q1 next year.
-
Onvansertib shows promising efficacy and safety in first-line RAS-mutated metastatic colorectal cancer, with higher response rates and deep tumor shrinkage at the 30 mg dose. A seamless phase 3 trial is planned, and the next major data update is expected in Q1 next year.
-
Onvansertib, a selective PLK1 inhibitor, is showing promising efficacy and safety in first-line RAS-mutated metastatic CRC, with key data expected in Q1 2026. The program targets a large unmet need, with a strong market opportunity and additional pipeline potential.
-
Onvansertib, a highly selective oral PLK1 inhibitor, demonstrated a 49% response rate in first-line RAS-mutated MCRC, nearly 20% above control, with deep and durable responses and minimal added toxicity. Supported by Pfizer and strong financials, a phase III trial is in planning.
-
Onvansertib, a selective PLK1 inhibitor, is showing strong efficacy and rapid, deep tumor responses in first-line metastatic colorectal cancer, with minimal toxicity and synergy with standard chemotherapy. The company plans a phase III trial and has a cash runway into Q1 2027.
-
The CRDF-004 phase 2 trial in first-line RAS-mutated mCRC showed a 49% confirmed ORR for 30 mg onvansertib plus standard of care, outperforming control and historical benchmarks. Onvansertib was well tolerated, with early PFS and response predictors supporting advancement to a registrational trial.
-
Onvansertib is showing promising efficacy and safety in first-line RAS-mutated colorectal cancer, with a pivotal trial design supported by the FDA and Pfizer partnership. Full enrollment is expected soon, with key efficacy updates and regulatory milestones anticipated in 2024.
Fiscal Year 2024
-
Cardiff 004 trial data showed a 64% ORR for the 30 mg Onvansertib arm, supporting a $40M capital raise and a strong cash position of $91.7M at year-end. Enrollment is nearly complete, with a mature data update expected in H1 2025 and FDA discussions planned.
-
Initial data from the Cardiff 004 phase II trial show a 64% response rate for the 30mg onvansertib arm in first-line RAS-mutated mCRC, nearly double the control, with favorable safety and deep tumor regressions. The company plans to expedite registration discussions with the FDA and recently secured $40 million in financing.
-
Cardiff-004 trial enrollment is on track, with an initial data readout expected later in 2024. Cash resources total $60.3 million, providing runway through Q3 2025. The pancreatic cancer program pivots to combine Onvansertib with NALIRIFOX, and preclinical data support further expansion.
-
Focused on first-line RAS-mutated metastatic colorectal cancer, onvansertib has shown high response rates and extended PFS in bevacizumab-naive patients. Ongoing trials, supported by Pfizer, aim for accelerated approval, with initial data expected later this year.